NASDAQ:MSLE Satellos Bioscience Q3 2026 Earnings Results & Report $5.78 -0.16 (-2.61%) As of 02:46 PM Eastern This is a fair market value price provided by Massive. Learn more. Satellos Bioscience missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.53 versus the -$0.44 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market OpensConference Call7:05 AM ET Satellos Bioscience EPS ResultsActual EPS-$0.53Consensus EPS -$0.44Beat/MissMissed by -$0.09One Year Ago EPSN/AEPS Beat Rate0 of last 4 quartersSatellos Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Satellos Bioscience Q3 2026 Earnings FAQ Did Satellos Bioscience beat earnings estimates for Q3 2026? Satellos Bioscience (NASDAQ:MSLE) reported earnings of -$0.53 per share for Q3 2026, missing the consensus estimate of -$0.44. The report was announced on Thursday, November 12, 2026. Satellos Bioscience Earnings HeadlinesFY2026 Earnings Forecast for MSLE Issued By HC WainwrightNovember 19 at 1:28 AM | americanbankingnews.comSatellos Bioscience (NASDAQ:MSLE) Stock Bumped Up to Sell by Wall Street ZenNovember 14, 2026 | americanbankingnews.comYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.November 19 at 1:00 AM | Reagan Gold Group (Ad)Satellos Bioscience's Phase 2 Data Readout Could Drive Significant Upside, Oppenheimer SaysNovember 13, 2026 | marketscreener.comMSatellos Bioscience: Q3 earnings snapshotNovember 12, 2026 | msn.comSatellos Reports Third Quarter 2026 Financial Results and Highlights Company ProgressNovember 12, 2026 | markets.businessinsider.comSee More Satellos Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email. Email Address About Satellos BioscienceSatellos Bioscience (NASDAQ:MSLE) is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment. Satellos is headquartered in Toronto, Canada. The company was co-founded by Frank Gleeson, who serves as its chief executive officer, and muscle stem-cell researcher Michael Rudnicki.View Satellos Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.